LONDON - Verici Dx plc (AIM:VRCI) announced today a proposed equity fundraising to raise approximately £2.5 million through a placing of new ordinary shares, according to a press release statement.
The company, which develops clinical diagnostics for organ transplant, will issue at least 700 million new ordinary shares at 0.35 pence per share, representing a 17.6 percent discount to the closing mid-price on Wednesday. The placing represents at least 47 percent of the company’s existing issued ordinary share capital.
Singer Capital Markets Securities Limited and Oberon Capital are acting as joint brokers and joint bookrunners for the placing, which was launched through an accelerated bookbuild today. The placing is not underwritten.
The company will also conduct a separate retail offer via the Winterflood Retail Access Platform to raise up to an additional £0.2 million through the issue of up to 57,142,857 new ordinary shares at the same price.
The company stated the net proceeds will be used to accelerate commercial growth and fund working capital requirements. Verici Dx plans to deploy funds across commercial personnel hiring, awareness raising initiatives, data generation through investigator-initiated trials, and general working capital including capital expenditure.
The company’s lead product Tutivia, a post-transplant acute rejection test, generated $3.0 million of unaudited revenue in its first full year of commercialization in fiscal year 2025. The test is used in 29 ordering centers across the United States and is reimbursed by Medicare at $2,650 per test.
Test volumes for Tutivia grew 32 percent sequentially to 392 in the first quarter of fiscal year 2026. The company is guiding to full year fiscal 2026 revenues of $5.1 million.
As of March 31, 2026, the company had unaudited net cash of approximately $1.3 million.
Harwood Capital LLP, a substantial shareholder, has indicated its intention to participate in the placing. Certain directors and officers are also expected to participate.
Admission of the placing shares to trading on AIM is expected to become effective at 8:00 a.m. on June 23, 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for VRCI plus thousands of other stocks and find your next hidden gem with massive upside.